FDA OKs Risankizumab for Crohn's Disease

(MedPage Today) -- The FDA has approved risankizumab (Skyrizi), an interleukin (IL)-23 inhibitor, for the treatment of moderately to severely active Crohn's disease, AbbVie announced on Friday.
The approval for Crohn's disease was based on phase...